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Androgen receptor (AR) splice variants (SV) have been implicated in the 
development of metastatic castration resistant prostate cancer and resistance 
to AR targeting therapies including abiraterone and enzalutamide. Agents 
targeting AR-SV are urgently needed to test this hypothesis and further 
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3. MAIN TEXT 
 
In this issue of Clinical Cancer Research, Yang and colleagues report that 
targeting the androgen receptor (AR) activation function-1 (AF-1) within the 
AR N-terminal domain (NTD) using EPI-002 overcomes molecular aberrations 
implicated in the development of metastatic castration resistant prostate 
cancer (mCRPC) (1). 
 
Prostate cancer is the second leading cause of cancer death in American 
men. The mainstay of treatment is androgen deprivation therapy and despite 
robust responses nearly all patients progress to fatal mCRPC. There is now 
incontrovertible evidence of ongoing AR signaling as patients progress to 
mCRPC with rising PSA, increased expression of AR co-regulators, AR 
amplification, AR activating mutations and increased steroidogenesis (Figure 
1) (2). This led to the development of abiraterone acetate (AA) and 
enzalutamide (EZ), which inhibit AR signaling in mCRPC and improve patient 
outcome. Despite these advances, responses can be short lived with 
resistance to both agents being common.  
Expression of constitutively active AR splice variants (AR-SV), of which AR 
splice variant 7 (AR-V7) has been reported to be the most abundant, have 
been postulated as critical for mCRPC biology and a key mechanism of 
resistance to current AR targeting therapies (Figure 1) (3, 4). Original studies 
suggested that AR-V7 heterodimerized with full length AR (AR-FL) to signal. 
Importantly, AR-V7 can homodimerize with itself and heterodimerize with 
other AR-SV to signal independently of AR-FL (5). AR-V7 lacks the C-terminal 
ligand-binding domain (LBD) but maintains an intact AF-1 domain and AR-V7 
overexpression in-vitro confers resistance to therapies targeting the AR LBD. 
AR-V7 levels increase as patients progress from hormone sensitive prostate 
cancer (HSPC) to mCRPC, and AR-V7 expression correlates with shorter 
overall survival, suggesting a key role in mCRPC biology (3). Moreover, AR-
V7 expression increases further after castration resistant disease progresses 
on AA or EZ, associating with treatment resistance (3, 4). Currently, all 
licensed therapies used in the treatment of mCRPC that modulate AR 
signaling do so through the AR LBD and have little or no activity against AR-
V7. 
There are a number of novel (beyond targeting the AR LBD) therapeutic 
strategies in pre-clinical development or early clinical trials in mCRPC (Figure 
1). Briefly, these include: (1) Inhibition of bromodomain and extraterminal 
domain proteins to downregulate AR-FL/AR-V7 expression (GSK525762, 
GSK2820151 and OTX015/MK-8628) (6); (2) Targeting HSP90 to deplete AR-
FL through proteasomal degradation and decreasing AR-V7 through the 
blockade of mRNA splicing (onalespib) (7); (3) Inhibiting AR-FL 
transactivation and reducing AR-FL/AR-V7 protein expression (TAS3681) (8): 
(4) Targeting deubiquitinating enzymes to promote AR-FL/AR-V7 degradation.  
Importantly, most of the transactivation function of AR stems from the AR AF-
1 domain, present in AR-FL and most AR-SV; strategies to target this, though 
challenging due to the AR NTD having an intrinsically unstructured nature and 
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lack of enzymatic activity, are exciting and have the potential to overcome 
aberrant AR signaling in mCRPC (9). EPI-001 and its analogs bind to Tau5 of 
AR AF-1 and block protein to protein interactions critical for AR transcriptional 
activity, inhibiting the growth of CRPC xenografts in mice (10). In this current 
report, Yang and colleagues report the ability of EPI-002, the single (2R, 20S) 
diastereoisomer of EPI-001, to overcome ongoing AR signaling in mCRPC 
(1). AR transcriptional activity is modulated by AR co-regulators, including the 
p160 steroid receptor co-activator (SRC) proteins and CBP/p300 that are 
elevated in prostate cancer and associated with poorer prognosis. EZ, and to 
a lesser extent EPI-002, inhibit hormone-dependent SRC-family and 
CBP/p300 co-regulator stimulation of AR transactivation albeit at relatively 
high concentrations (10 and 25 M respectively). Moreover, EZ and EPI-002 
inhibited hormone-dependent transactivation of AR NTD and AR LBD gain-of-
function point mutants (1). The authors should be commended on their 
rigorous study of clinically relevant aberrations, although EPI-002 had similar 
activity on AR signaling to currently licensed, well-tolerated, therapies that 
improve survival of patients with mCRPC. The question remains whether 
targeting the AR AF-1 will provide clinically significant gains over current AR 
LBD targeting therapies for AR aberrations that do not confer resistance to 
these treatments. 
 
In contrast, AR-SV and in particular AR-V7 has been implicated in resistance 
to current therapies including AA and EZ (4). AR-FL and AR-V7 have distinct 
transcriptional activities in mCRPC. In this study Yang et al used EZ-resistant 
LNCaP95 cells that express both AR-FL and AR-V7 to demonstrate that EPI-
002 and EZ both reduce the expression of genes regulated by AR-FL (PSA 
and FKBP5). Unlike EZ, which did not do this, EPI-002 reduced the 
expression of genes reported to be distinctly regulated by AR-V7 (UBE2C and 
CDC20). Furthermore, in EZ-resistant LNCaP95 mouse xenografts, EPI-002 
significantly delayed the growth of tumors (without causing growth regression) 
when compared to EZ (1). Yang and colleagues have presented convincing 
pre-clinical evidence that targeting the AR NTD AF-1 with EPI-002 decreases 
AR-V7 transcriptional activity and delays growth in prostate cancer models 
resistant to current therapies supporting the evaluation of this agent in clinical 
trials in patients with AR-SV expressing mCRPC.  
 
Concerns remain, nevertheless, with regards to the high concentrations of 
EPI-002 required to modulate AR activity in these studies (25 M) and 
whether this can be recapitulated in clinical studies at tolerable doses. This 
has been raised by studies indicating that EPI compounds covalently bind not 
only to the AF-1 but also to proteins other than AR and that EP-001 alkylates 
thiols under basic or neutral conditions (11). Notably, EPI-002 contains a 
chemically reactive chlorohydrin that is essential for biological activity; indeed, 
EPI analogs comprising the chlorohydrin moiety covalently bind to the AF-1 
domain of AR in cells whereas analogs lacking the chlorohydrin do not (10). 
Whilst these cell-based studies did not reveal an abundance of other protein 
targets, application of unbiased mass-spectrometry-based proteomics could 
further inform on the specificity of EPI-002 and its analogs. Interestingly, many 
successful marketed drugs rely upon covalent binding to their target proteins 
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(12). Commonly, minimization of off-target effects for such agents relies upon 
initial reversible, high affinity and selective binding to the desired protein 
target followed by irreversible covalent binding; furthermore, low efficacious 
exposure is likely to reduce off-target tolerability issues by avoiding saturation 
of the endogenous protective glutathione-mediated trapping mechanism for 
chemically reactive species. Whether EPI-506 (prodrug of EPI-002) will 
benefit from factors such as these remains to be demonstrated. 
 
The current phase I/II trial (NCT02606123) of EPI-506 in patients with 
mCRPC who have progressed on AA and/or EZ will be critical in alleviating 
these concerns. This study will determine whether EPI-506 is well tolerated 
with a favorable pharmacokinetic profile. Furthermore, it will be important that 
biomarker-driven pharmacodynamics studies recapitulate the preclinical data 
presented by Yang et al demonstrating modulation of AR-V7 oncogenic 
signaling. The majority of patients resistant to AA and EZ demonstrate 
increased AR-V7 expression; biomarker studies embedded in this trial 
evaluating AR-V7 mRNA and protein expression will be key to identify 
patients most likely to respond to EPI-506 (3, 4). Patients whose cancers 
have decreased AR-FL/AR-V7 expression may have alternative AR 
independent mechanisms of resistance. Such patient selection biomarkers will 
be key to future registration studies. Taken together, if drugs targeting AR AF-
1, such as EPI-506, show AR-SV signaling blockade at tolerable doses with 
durable antitumor activity in patients whose tumors express AR-SV, these 
agents have the potential to transform the treatment of advanced prostate 
cancer; not only in the late stage setting but also in earlier stages of this 
disease since studies indicate that AR-SV expression can be induced soon 
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Figure 1: Novel therapeutic strategies to block persistent androgen 
receptor signalling in metastatic castration resistant prostate cancer 
 
Androgen receptor (AR) gene amplification and mutation leads to increased 
AR protein expression and gain-of-function AR aberrations including 
activating protein mutants (AR MUT). Changes in mRNA splicing generate 
constitutively active AR splice variants (AR-SV). Androgens (A) and 
coregulators (CR) regulate AR protein activity. AR, AR MUT and AR-SV bind 
androgen response elements (ARE) and regulate oncogenic AR signaling 
driving progression to metastatic castration resistant prostate cancer 
(mCRPC) and therapeutic resistance. AR protein stability is regulated by post-
translational modifications (PTM) and proteasomal degradation that can be 
modulated by the HSP90 chaperone machinery and deubiquitinating enzymes 
(DUB). Mechanisms implicated in the development of mCRPC are shown 
(blue fill boxes). Novel therapeutic strategies in pre-clinical development and 
early phase clinical trials to overcome aberrant AR signalling in mCRPC are 
shown (red). 
 
 
